Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 7Sarcoma 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 8X-Rays 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6olaparib 4ulixertinib 3trametinib 3palbociclib 3larotrectinib 3ivosidenib 3erdafitinib 3dabrafenib 3Vemurafenib 3tipifarnib 2tazemetostat 2selpercatinib 2ensartinib 2durvalumab 2Nivolumab 2LY3023414 2Gemcitabine 2Doxorubicin 2Docetaxel 2Cisplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × avapritinib × Gastrointestinal × Clear all
NCT04714086 2024-10-24

Expanded Access Program for Avapritinib

Blueprint Medicines Corporation

No longer available
CNSGastrointestinalSarcoma

Glioma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡